sutent

/Tag:sutent

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By | 2018-07-06T14:36:03+00:00 September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

The heart of the matter: Cardiac health for GIST patients

The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To ensure [...]

By | 2016-03-21T14:39:38+00:00 February 10th, 2016|GIST Education, Newsletter, Side Effects|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By | 2018-07-06T13:59:34+00:00 January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|

Our Decision to Enter Hospice

I’ve been thinking a lot about writing this article. The last thing I want to do is cause worry or pain to anyone reading this. Then I thought of all the people who could possibly benefit in the future from knowing ahead of time what we didn’t know at the time we needed to know it.

By | 2018-07-06T13:30:18+00:00 June 11th, 2013|Coping with GIST, News, Sutent|

Stivarga becomes first FDA-approved third-line drug treatment for GIST

The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.

By | 2014-09-14T11:30:49+00:00 April 1st, 2013|Drug Treatment, News, Side Effects, Stivarga|

LRG Survey Seeks to Understand Differences in Sutent Dosage Schedules

The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.

By | 2016-03-14T12:05:06+00:00 January 9th, 2013|News, Sutent|

Recent Posts

Upcoming Events

  1. Michigan GDOL 2018

    October 27 @ 8:00 AM - 3:00 PM